<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CHOLIC ACID " rxcui="1440856">
<ATC code="A05AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Antagonist effect of the barbiturate</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FOLATES" code="V03-" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)

In cases of previous treatment with the pheyntoin and the addition of phenobarbital or of primidone, unpredictable changes:

--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.

--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia with increased risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
